Market Overview

UPDATE: Dawson James Initiates Galena Biopharma at Market Outperform

Share:
Related GALE
Galena Biopharma Inducts Mary Ann Gray To Its Board
Galena Biopharma 2016 Outlook Focuses On 'High Value' Cancer Immunotherapy Pipeline

Dawson James initiated coverage on Galena Biopharma (NASDAQ: GALE) with a Buy rating and a $3 price target.

Dawson James commented, "We believe investors have yet to fully appreciate NeuVax's clinical potential and chance of success in the Phase III PRESENT study currently underway. After assessing the NeuVax Phase II data on hand and speaking with Company management, we believe Galena has managed to implement several key insights gained from prior trials into in the Phase III PRESENT study, ignificantly improving its likelihood of success."

Galena Biopharma closed at $1.68 on Monday.

Latest Ratings for GALE

DateFirmActionFromTo
Mar 2016Roth CapitalMaintainsBuy
Dec 2015Cantor FitzgeraldUpgradesSellHold
Nov 2015OppenheimerUpgradesPerformOutperform

View More Analyst Ratings for GALE
View the Latest Analyst Ratings

Posted-In: Dawson James iAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (GALE)

View Comments and Join the Discussion!